11:42 AM EST - RepliCel Life Sciences Inc. : Announced that its European Phase 1 study of intradermal injections of RCS-01 to treat aged and sun damaged skin has been initiated at the IUF Leibniz-Institut für umweltmedizinische Forschung GmbH in Germany. RepliCel Life Sciences Inc.
shares V.RP are trading unchanged at $0.33.
